加载中
NASDAQHealthcareMedical - Healthcare Information Services
最新数据
US$2.245
−US$0.095 · -4.06%
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
前收盘价
US$2.245
−US$0.095 · -4.06%
盘后
US$2.3657
+US$0.1207 · +5.38%
10月12日 18:14 ET
盘中时间采用ET。市场数据可能有所延迟。
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
日内区间
当前US$2.245
52周区间
当前US$2.245
盘中时间采用ET。市场数据可能有所延迟。
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
日内区间
当前US$2.245
52周区间
当前US$2.245
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7.57万 USD | 4.57万 USD | 7.54万 USD | 6.04万 USD | 6.03万 USD |
| 销货成本 | 29.63万 USD | 12.98万 USD | 7.57万 USD | 6.53万 USD | 6.92万 USD |
| 毛利 | −22.06万 USD | −8.4万 USD | −324 USD | −4854 USD | −8883 USD |
| 研究与开发 | 1.03万亿 USD | 88.88万 USD | 87.33万 USD | 106.8万 USD | 78.79万 USD |
| 销售、一般及管理费用 | 6.03万亿 USD | 458.53万 USD | 400.23万 USD | 448.87万 USD | 215.63万 USD |
| 营业费用 | 683.18万 USD | 542.9万 USD | 487.57万 USD | 555.67万 USD | 294.42万 USD |
| 利息收入 | 41.11万 USD | 318 USD | 172 USD | 2511 USD | — |
| 利息支出 | — | 53.55万 USD | 60.83万 USD | 150.75万 USD | 47.65万 USD |
| 折旧和摊销 | 22.74万 USD | 19.31万 USD | 16.27万 USD | 14.36万 USD | 18.64万 USD |
| 营业利润 | −705.24万 USD | −551.3万 USD | −487.6万 USD | −556.16万 USD | −295.3万 USD |
| 净利润 | −723.36万 USD | −699.29万 USD | −491.14万 USD | −706.86万 USD | −495.03万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
